CAR-T for CNS lymphoma – pro
CAR-T therapy is effective but not long-lasting in the brain. At this time, only case reports are in the literature. Several clinical trials on CAR T-cell therapy for primary and secondary CNS lymphoma are currently ongoing. Extrapolated from the available preliminary data, an overall acceptable safety profile with considerable anti-tumor effects might be expected. Whether these beneficial anti-tumor effects are as long-lasting as in animal models is currently in doubt, and the immunosuppressive tumor microenvironment of the brain may be among the most pivotal factors limiting efficacy of CAR T-cell therapy in CNS lymphoma.
Tongual LI et al, CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain. Front. Oncol., 04 August 2020
LETTER TO BLOOD| FEBRUARY 3, 2022, CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network
Blood (2022) 139 (5): 792–796.
Karschnia P, Blobner J, Teske N, et al. CAR T-Cells for CNS Lymphoma: Driving into New Terrain?. Cancers (Basel). 2021; 13(10): 2503. Published 2021 May 20.